By using our website, you are agreeing to cookies being stored and Google Analytics being used on your device in order to offer the best possible service. You can find more information on thishere.
Austria.
Where Your Profits Grow Sky High.

Novartis invests EUR 100 million

Sandoz plant in Schaftenau © Novartis

The subsidiary will be expanded to include, amongst other things, an integrated cell culture production, creating 190 new jobs. There originator biologicals from Novartis and biosimilars from Sandoz will be produced for the global market.

“Originator biologicals and biosimilars are the future of modern medicine. Novartis is a global leader in production and development in this field. Thanks to this investment we are even more pleased with the fact that the future of medicine will take place in Austria”, says Ard van der Meij, Country President of Novartis Austria.

Austrian quality for the world market

The Schaftenau plant is of major importance for Novelis due to the production of originator biologicals and biosimilars. This includes a focus product from Novartis pharmaceuticals for the therapy of psoriasis, psoriasis arthritis and Bektherev’s disease and two cost efficient Sandoz biosimilars. One of them is for the treatment of certain forms of blood cancer and immunological diseases, the other for the treatment of rheumatoid arthritis and other rheumatic illnesses. In 2014 and 2015, a global microparticle technology center and a state-of-the-art biologicals production for ready-to-fill syringes were open, and the production facilities were continuously expanded.

Share on Facebook Share on Facebook Share on Twitter Share on Twitter Share on Linkedin Share on Linkedin

Testimonials

Events

Meet us at events, seminars and trade shows - worldwide.

  • 5. Mittelstandsforum Nordrhein-Westfalen

    26.11.2020/ 12:00 - 17:45, Online Conference

  • Online konzultačné dni venované Rakúsku

    03.12.2020, online

Austria Map

Find the perfect location for your company

Investments in research and innovation are the basis of success for our company. The business location of Austria offers us an attractive environment of development funding, non-university research facilities and access to optimally trained engineers and university progrlammes“, states Markus Staeblein, Managing Director of NXP Austria GmbH.

NXP Semiconductors Austria GmbH

Logo: NXP Semiconductors Austria GmbH
More testimonials

news from the business location Austria

Restarting Growth in Central and Eastern Europe: Drivers and Barriers

Professor Arnold Schuh (Vienna University of Economics and Business) shares his insights on the economic recovery in CEE.

Support measures for companies affected by COVID-19

To stimulate the economy, either new programs may be established as a result of the draft law or existing support programs (e.g. aws, ÖHT) will be expanded. All measures introduced are intended to be applicable immediately and will be in force until the end of 2020. The measures currently introduced include the following areas:

More news All blog posts